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NEWS
Frederick W. Alt received the 2015 
Szent-Györgi Prize for Progress in Cancer 
Research
Peter Scully, Jie Zhao* and Sujuan Ba
Abstract 
The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National 
Foundation for Cancer Research (NFCR)—a leading cancer research charitable organization in the United States that 
is committed to supporting scientific research and public education relating to the prevention, early diagnosis, better 
treatments, and ultimately, a cure for cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher, 
nominated by colleagues or peers, who has contributed outstanding, significant research to the fight against cancer, 
and whose accomplishments have helped improve treatment options for cancer patients. The Prize also promotes 
public awareness of the importance of basic cancer research and encourages the sustained investment needed to 
accelerate the translation of these research discoveries into new cancer treatments. This report highlights the pio-
neering work led by the 2015 Prize winner, Dr. Frederick Alt. Dr. Alt’s work in the area of cancer genetics over four 
decades has helped to shape the very roots of modern cancer research. His work continues to profoundly impact the 
approaches that doctors around the globe use to diagnose and treat cancer. In particular, his seminal discoveries of 
gene amplification and his pioneering work on molecular mechanisms of DNA damage repair have helped to usher in 
the era of genetically targeted therapy and personalized medicine.
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In recognition for his pioneering work in the area of 
cancer genetics, Dr. Frederick Alt was awarded the 2015 
Szent-Györgyi Prize for Progress in Cancer Research. Dr. 
Alt’s research is foundational to the modern understand-
ing of cancer as a genetic disease, and has led directly to 
the era of precision medicine. The Prize was presented 
at a ceremony in Washington, D.C., on April 29, 2015, at 
The National Press Club.
The Szent-Györgyi Prize for Progress in Cancer 
Research is a prestigious scientific award established by 
the National Foundation for Cancer Research (NFCR)—
a leading cancer research charitable organization in the 
United States that has gained international recognition 
for its vision and unique approaches to accelerating can-
cer research toward a cure. The Prize is awarded annually 
to a scientist, nominated by colleagues or peers, who has 
contributed outstanding, significant research to the fight 
against cancer, and whose accomplishments have helped 
improve treatment options for cancer patients.
The Prize is named in honor of NFCR co-founder 
Albert Szent-Györgyi, M.D., Ph.D., who won the Nobel 
Prize for Science and Medicine in 1937 for his discovery 
of vitamin C. The Prize and the surrounding ceremony 
also serve to promote public awareness of the importance 
of basic cancer research and to encourage the sustained 
investment needed to accelerate the translation of these 
research discoveries into new cancer treatments.
Since its establishment in 2006, the Szent-Györgyi Prize 
has been awarded to 11 outstanding cancer researchers 
from around the world. Among the past awardees is Dr. 
Zhu Chen, chairman of the Chinese Medical Association 
and former Minister of Health of China, who won the 
2012 Prize together with his mentor, Dr. Zhen-Yi Wang.
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The 2015 Szent‑Györgyi Prize
In 2015, the Szent-Györgyi Prize for Progress in Cancer 
Research was awarded to Frederick Alt, Ph.D., Professor 
of Genetics at Harvard Medical School, Director of the 
Program in Cellular and Molecular Medicine at Boston 
Children’s Hospital, and Howard Hughes Medical Insti-
tute Investigator (Fig.  1). Dr. Alt’s groundbreaking work 
in cancer genetics over four decades has helped to shape 
the very roots of modern cancer research. Today, that 
work continues to bear fruit, profoundly impacting the 
approaches that doctors use to diagnose and treat cancer.
NFCR’s selection committee was unanimous in its 
decision to recognize Dr. Alt, whose work has proven 
foundational to the modern understanding of cancer—
not only how the lethal disease forms but also how it can 
become resistant to treatment. In particular, his seminal 
discoveries of gene amplification and his pioneering work 
on molecular mechanisms of DNA damage repair have 
helped to usher in the era of genetically targeted therapy 
and personalized medicine.
“Dr. Alt’s work has uncovered and explained some of 
the most foundational chemistry of life, and throughout 
his career he has always been focused on the implications 
for cancer,” said Sujuan Ba, Ph.D., Co-chair of the 2015 
Szent-Györgyi Prize Selection Committee and President 
of NFCR. “His vision and talent were instrumental in 
bringing cancer research into the modern era, and we are 
proud to present him with this award.”
In bestowing this award, the Prize Selection Commit-
tee recognizes the entire body of work that Dr. Alt has 
amassed. “Dr. Alt is a consistently outstanding scientist 
throughout his career,” said Dr. James Allison, Executive 
Director of the Immunotherapy Platform at MD Ander-
son Cancer Center, winner of the 2014 Szent-Györgyi 
Prize, and Chair of the 2015 Prize Selection Commit-
tee. “The genetic processes Dr. Alt described are central 
to understanding the mechanisms that cause cancer, and 
have ultimately led to an entire class of targeted therapy 
and associated diagnostics that are providing benefit to 
countless cancer patients.”
Frederick W. Alt: cancer genetics pioneer
Dr. Frederick Alt is currently the Director of the Pro-
gram in Cellular and Molecular Medicine (formerly the 
Immune Disease Institute) at Boston Children’s Hospital. 
Dr. Alt has been Professor of Genetics at Harvard Medi-
cal School since 1991 and Charles A. Janeway Professor 
of Pediatrics at Boston Children’s Hospital since 1993. 
Prior to 1991, Dr. Alt was on the Faculty at Columbia 
University. He earned his Ph.D. with distinction from the 
Department of Biological Sciences at Stanford University 
in 1977. Dr. Alt is a member of the National Academy of 
Sciences, the Institute of Medicine of the National Acad-
emies, and a fellow of the American Academy of Arts and 
Sciences, the American Academy of Microbiology, and 
the American Association for the Advancement of Sci-
ence. He is also an investigator at the Howard Hughes 
Medical Institute.
Dr. Alt has won numerous honors for biomedical 
research, including the Stanford University Medical 
Center Arthur Kornberg and Paul Berg Lifetime Achieve-
ment Award in Biomedical Science and the National 
Cancer Institute’s Alfred Knudson Award for “pioneering 
contributions that have revolutionized the field of can-
cer genetics.” Each year, the Cancer Research Institute of 
New York presents the Frederick W. Alt Award for New 
Discoveries in Cancer Immunology in his honor. Dr. Alt’s 
impact extends far beyond his own laboratory, for not 
only is he an outstanding researcher; he is also an exem-
plary teacher. In 2003, he received the American Associa-
tion of Immunologists Excellence in Mentoring Award. 
Dr. Alt has mentored over 100 students and research fel-
lows, many of whom have become leaders in immunol-
ogy, genetics, or cancer biology.
For Dr. Alt, cancer research has always been a personal 
endeavor. During his remarks, Dr. Alt spoke of how can-
cer claimed the lives of both his parents when he was a 
young child (Fig. 2). “It did make a big impact,” said Dr. 
Alt, “and I wanted to become a cancer researcher.”
Drug resistance was a well-known problem in cancer 
treatment when Dr. Alt’s career began. His early research 
Fig. 1 From left to right Dr. Sujuan Ba, Co-chair of the 2015 Szent-
Györgyi Prize Selection Committee and President of the National 
Foundation for Cancer Research (NFCR); Dr. Frederick Alt, winner of 
the 2015 Szent-Györgyi Prize; and Dr. Webster Cavenee, winner of the 
2007 Szent-Györgyi Prize
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sought to understand how cancer cells become resist-
ant to the drug methotrexate, and it was animated by 
the “somewhat heretical notion that cancer cells might 
be able to increase their numbers of gene copies.” At 
that time, in the early 1970s, conventional wisdom held 
that each person had exactly two copies of each gene—
one copy from their mother and the other from their 
father—and that their genome was otherwise fixed and 
unchangeable.
After building the technology to probe cells for indi-
vidual genes, Dr. Alt applied this technology to cancer 
cells that had been treated with methotrexate. “We found 
that cells that are very resistant have hundreds or thou-
sands of copies of the dihydrofolate reductase gene which 
confers resistance,” said Dr. Alt. “When we took the cells 
out of the drug, they actually lost the gene copies, really 
showing that mammalian cancer cells could have unsta-
ble genomes. They could gain genes when they were put 
under selection for drug resistance, and they could lose 
them when it was taken away. That was really a shocking 
result.”
Dr. Alt’s discovery of gene amplification in chemother-
apy-resistant cancer cells served to overthrow the old 
concept of a fixed genome, suggesting instead that can-
cer cells could change their genes to evolve resistance to 
treatments like methotrexate.
The story became even more interesting when the same 
pattern of amplified genes was discovered in the child-
hood cancer neuroblastoma. “We knew from our metho-
trexate resistance research what amplified genes looked 
like under a microscope,” said Dr. Alt, but it was not clear 
which gene had been amplified in these tumors. It was 
at this time that Dr. Alt made the connection between 
gene amplification and carcinogenesis. “The idea we had 
was that there would be a gene that actually caused the 
cancer—not one that would cause drug resistance, but 
one that made the cancer grow better,” he said. This idea 
built directly off the recent discovery of viral oncogenes 
by previous Szent-Györgyi Prize winner Dr. Peter Vogt.
Dr. Alt and his colleagues identified that the amplified 
gene in neuroblastoma was related to the viral onco-
gene myc, so they named it neuroblastoma-myc or n-
myc. “That was extremely satisfying for us,” said Dr. Alt, 
“because it showed that for gene amplification it was not 
only a mechanism by which cancer cells become drug-
resistant but also a mechanism by which they get gener-
ated.” Today, genomic instability is recognized as one of 
the hallmarks of cancer.
Equally important to cancer research has been Dr. Alt’s 
work on the critical DNA repair mechanism called “non-
homologous end joining” (NHEJ). Dr. Alt not only made 
the initial experimental findings that led to the discovery 
of this pathway but also carried out an ingenious series of 
experiments over many years in his lab in Boston, taking 
it apart piece by piece to understand how it works. This 
work linked NHEJ to protecting against a specific type 
of DNA damage called translocation, which is a major 
component of many cancers, especially leukemia and 
lymphoma.
Both amplified genes and translocated genes are key 
components of the Precision Medicine paradigm, which 
is at the heart of 21st century medicine. By identifying 
the source of genetic abnormalities that drive both can-
cer development and drug resistance, Dr. Alt’s insights 
helped to revolutionize cancer diagnostics and treat-
ment. His discoveries led to a wholly new approach to 
treating cancer—identifying these genetic abnormalities, 
and then selecting new drugs that target each specifically.
In his closing remarks at the award ceremony, Dr. Alt 
said “Now is the time. We have the opportunity, and if 
we get the support I’m confident that basic cancer-driven 
research will help exploit this current technological 
explosion, [producing] more and more breakthroughs at 
an ever-increasing pace.” Through events like the Szent-
Györgyi Prize, NFCR is working towards this goal, by 
raising public awareness of research and encouraging 
sustained investment in the future of basic science.
The 2015 Szent-Györgyi Prize Selection Committee 
was chaired by James Allison, Ph.D., and co-chaired by 
Sujuan Ba, Ph.D. Other selection committee members 
included leaders in cancer research and drug develop-
ment from academic institutes and biotech and pharma-
ceutical industries: Webster K. Cavenee, Ph.D., Ludwig 
Institute for Cancer Research; Carlo M. Croce, M.D., The 
Ohio State University; George D. Demetri, M.D., Dana-
Farber Cancer Institute; Richard Gaynor, M.D., Eli Lilly 
and Company; Thomas J. Kelly, M.D., Ph.D., Memo-
rial Sloan-Kettering Cancer Center; Mary-Claire King, 
Fig. 2 Dr. Frederick Alt, winner of the 2015 Szent-Györgyi Prize, gave 
an acceptance speech at the Award Ceremony held on April 29, 2015 
in Washington D.C.
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Ph.D., University of Washington School of Medicine; 
Scott M. Lippman, M.D., Moores Cancer Center; Tak 
W. Mak, Ph.D., Ontario Cancer Institute; Alex Matter, 
M.D., Experimental Therapeutics Center & D3, A*STAR 
Singapore; Scott D. Patterson, Ph.D., Amgen, Inc.; Philip 
Tsichlis, M.D., Tufts University School of Medicine; Peter 
K. Vogt, Ph.D., The Scripps Research Institute; Owen N. 
Witte, M.D., David Geffen School of Medicine, University 
of California, Los Angeles; Qimin Zhan, M.D., State Key 
Laboratory of Molecular Oncology, China; and General 
Secretary Yi Michael Want, M.D., Ph.D., NFCR.
Previous recipients of the Szent‑Györgyi Prize 
for Progress in Cancer Research
2014—James Allison, Ph.D., Chairman of the Immu-
nology Department and Executive Director of the Immu-
notherapy Platform for the “Moon Shots” Program, 
University of Texas MD Anderson Cancer Center, Hou-
ston, TX, US.
2013—Alex Matter, M.D., Chief Executive Officer, 
Experimental Therapeutics Centre, Agency for Science, 
Technology and Research (A*STAR), Singapore.
2012—Zhu Chen, M.D., Ph.D., Professor, School of 
Medicine of Shanghai Jiao Tong University; Chairman, 
Chinese Medical Association; former Minister of Health 
of China, Shanghai, P.R. China.
2012—Zhen-Yi Wang, M.D., Professor, School of 
Medicine of Shanghai Jiao Tong University; Honorary 
Director, Shanghai Institute of Hematology, Shanghai, 
P.R. China.
2011—Beatrice Mintz, Ph.D., Professor and Jack 
Schultz Chair in Basic Science, Fox Chase Cancer Center, 
Philadelphia, PA, US.
2010—Peter K. Vogt, Ph.D., Professor, Department 
of Molecular and Experimental Medicine, The Scripps 
Research Institute, La Jolla, CA, US.
2009—Ronald A. DePinho, M.D., President, University 
of Texas MD Anderson Cancer Center, Houston, TX, US.
2008—Carlo M. Croce, M.D., Director, Human Cancer 
Genetics Program; Director, Institute of Genetics, The 
Ohio State University, Columbus, OH, US.
2007—Webster K. Cavenee, Ph.D., Director, Ludwig 
Institute for Cancer Research, San Diego Branch; Distin-
guished Professor, University of California, San Diego, 
CA, US.
2006—Harold F. Dvorak, M.D., Mallinckrodt Professor 
Emeritus of Pathology, Harvard Medical School; Chief, 
Department of Pathology, Beth Israel Deaconess Medical 
Center, Boston, MA, US.
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